Immutep (IMMP) reports positive IMP761 Phase I study update

Rhea-AI Filing Summary

Immutep Limited furnishes a Form 6-K that includes an exhibit titled “Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study.” This indicates the company is providing investors with a positive clinical update on IMP761, which it describes as a first-in-class LAG-3 agonist antibody being studied for autoimmune diseases in a Phase I trial. The detailed results and implications of this Phase I study are contained in the attached exhibit, which is referenced but not reproduced here.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date as December 22, 2025

Commission File Number 001-35428

IMMUTEP LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

Level 32, Australia Square

264 George Street, Sydney

NSW 2000, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐   No ☒

If “Yes” is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: December 22, 2025

IMMUTEP LIMITED
By:		/s/ Marc Voigt
Name:		Marc Voigt
Title:		Chief Executive Officer

FAQ

What did Immutep Limited (IMMP) report in this Form 6-K?

Immutep Limited submitted a Form 6-K that includes an exhibit titled “Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study,” providing a positive clinical update on IMP761.

What is IMP761 according to the Immutep (IMMP) Form 6-K?

IMP761 is described as a first-in-class LAG-3 agonist antibody being developed for autoimmune diseases, with the update coming from a Phase I study.

What stage of development is IMP761 in based on this Immutep filing?

The exhibit referenced in the Form 6-K provides a positive update on IMP761 from a Phase I study, indicating it is in Phase I clinical testing.

Does the Immutep Form 6-K include detailed Phase I results for IMP761?

The Form 6-K notes an exhibit titled as a positive update from a Phase I study of IMP761. The detailed results are contained in that exhibit, which is referenced but not detailed in this text.

Who signed the Immutep Limited (IMMP) Form 6-K?

The Form 6-K is signed on behalf of Immutep Limited by Marc Voigt, who is identified as the company’s Chief Executive Officer.